Literature DB >> 7587653

Molecular biology of somatostatin receptors.

G I Bell1, K Yasuda, H Kong, S F Law, K Raynor, T Reisine.   

Abstract

The diverse physiological effects of somatostatin are mediated by a family of cell surface receptors that bind somatostatin selectively and with high affinity. The somatostatin receptors are members of the seven transmembrane segment receptor superfamily and molecular cloning studies have identified five types, designated sstr1-5. The human somatostatin receptors vary in size from 364 (sstr5) to 418 (sstr3) amino acids with 46-61% amino acid identity between receptors, and 105 amino acids are invariant. The sequences of the seven putative alpha-helical membrane-spanning domains are more highly conserved than those of the extracellular N- and intracellular C-terminal domains. Two forms of sstr2 have been identified in the mouse, sstr2A and sstr2B, which differ in size and sequence of the intracellular C-terminal domain. These two forms of sstr2 are products of a common gene and are generated by alternative splicing with sstr2A and sstr2B being the products of the unspliced and spliced forms, respectively, of sstr2 mRNA. Thus, functional diversity within the somatostatin receptor family may result from the expression of multiple types as well as from alternative splicing. The five somatostatin receptors have distinct patterns of expression in the central nervous system and peripheral tissues. They have also been expressed in vitro and shown to have different pharmacological properties. Somatostatin analogues selective for sstr2, sstr3 and sstr5 have been identified which will facilitate in vivo studies of the functions of these somatostatin receptors. Such studies to date suggest that sstr2 mediates inhibition of growth hormone secretion and sstr5 mediates inhibition of insulin secretion. The molecular cloning and functional characterization of the somatostatin receptor family is a first step in elucidating the diverse effects of somatostatin on cellular functions.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7587653     DOI: 10.1002/9780470514733.ch5

Source DB:  PubMed          Journal:  Ciba Found Symp        ISSN: 0300-5208


  10 in total

Review 1.  The epidural and intrathecal administration of somatotrophin-release inhibiting factor: native and synthetic analogues.

Authors:  D P Beltrutti; S Moessinger; G Varrassi
Journal:  Curr Rev Pain       Date:  2000

2.  VeloceGenomics: an accelerated in vivo drug discovery approach to rapidly predict the biologic, drug-like activity of compounds, proteins, or genes.

Authors:  Ruben Papoian; Andreas Scherer; Muriel Saulnier; Frank Staedtler; André Cordier; Francois Legay; Gerard Maurer; Joerg Staeheli; Jacky Vonderscher; Salah-Dine Chibout
Journal:  Pharm Res       Date:  2005-09-22       Impact factor: 4.200

Review 3.  Gastrointestinal hormones regulating appetite.

Authors:  Owais Chaudhri; Caroline Small; Steve Bloom
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-07-29       Impact factor: 6.237

Review 4.  A role for the neuropeptide somatostatin in the neurobiology of behaviors associated with substances abuse and affective disorders.

Authors:  Stacey L Robinson; Todd E Thiele
Journal:  Neuropharmacology       Date:  2020-02-03       Impact factor: 5.250

5.  Attenuation of insulin secretion by insulin-like growth factor 1 is mediated through activation of phosphodiesterase 3B.

Authors:  A Z Zhao; H Zhao; J Teague; W Fujimoto; J A Beavo
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

6.  Somatostatin in inflammatory bowel disease.

Authors:  J D van Bergeijk; J H Wilson
Journal:  Mediators Inflamm       Date:  1997       Impact factor: 4.711

7.  Gain of chromosome arm 17q is associated with unfavourable prognosis in neuroblastoma, but does not involve mutations in the somatostatin receptor 2(SSTR2) gene at 17q24.

Authors:  F Abel; K Ejeskär; P Kogner; T Martinsson
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

8.  Somatostatin Decorated Quantum Dots for Targeting of Somatostatin Receptors.

Authors:  Ahmed Abdelfattah Hafez Abdellatif; Wael Abdellah Abdelhafez; Hatem Abdelmunsef Sarhan
Journal:  Iran J Pharm Res       Date:  2018       Impact factor: 1.696

Review 9.  Somatostatin receptors as a new active targeting sites for nanoparticles.

Authors:  Ahmed A H Abdellatif; Sa'ed M Aldalaen; Waleed Faisal; Hesham M Tawfeek
Journal:  Saudi Pharm J       Date:  2018-05-31       Impact factor: 4.330

10.  Indium-111-labelled octreotide scintigraphy in the diagnosis and management of non-iodine avid metastatic carcinoma of the thyroid.

Authors:  J A Christian; G J R Cook; C Harmer
Journal:  Br J Cancer       Date:  2003-07-21       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.